Steady-State Pharmacokinetics of Rifaximin 550 mg Tablets in Healthy and Hepatically Impaired Subjects

NCT03818672 PHASE4 TERMINATED Results posted

The primary objective of this study is to characterize the steady state plasma

Details

Lead sponsor	Bausch Health Americas, Inc.
Phase	PHASE4
Status	TERMINATED
Enrolment	5
Start date	Tue Jan 29 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Sun Feb 02 2020 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Severe Hepatic Impairment

Interventions

• Rifaximin

Countries

United States